Learn More
506 Background: Extinction of HER2 signaling in HER2 driven BC may be curative. Alternative activation pathways (HER1, HER3) & mutated downstream signal transducers allow resistance to therapy. (More)
BACKGROUND Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as(More)